The ingredient and the finished product
PT-141 was an earlier name for bremelanotide; Vyleesi is the name of the approved finished medicine.
As checked on November 3, 2026, the Vyleesi presentation is a prefilled device for an injection beneath the skin.
The name and form both belong in the discussion. A search page may use the ingredient name while leaving the actual preparation unclear. Ask for that missing detail before trying to compare evidence or cost.
What compounding changes
A pharmacist or physician compounds a drug by preparing it, rather than supplying the approved finished product.
A compounded bremelanotide product is not FDA-approved; that status was checked on November 3, 2026.
For these preparations, FDA does not assess the finished drug’s quality, safety or benefit before marketing.
This does not mean every instance of compounding is unlawful.
That does not settle whether a given prescription meets the rules. Ask about the legal fit as well as the approval status.
For a proposed compounded version, ask what individual need it is meant to address and who will prepare it. Ask how the prescriber reached that conclusion. A shared ingredient is not a complete answer to either question.
The ingredient test is only part of the rule
For a prescription naming one patient, the raw-ingredient test is a legal check on what a compounder may start with. For example, when there is no official standard for the ingredient, this part of the rule can accept an ingredient from an approved medicine. Bremelanotide is an ingredient in approved Vyleesi. That alone does not settle the other legal requirements.
The federal copy restriction was checked on November 3, 2026. It limits making near-copies of available drugs regularly or in excessive amounts.
For compounding with a prescription naming one patient, the prescriber must decide that changing the drug makes an important difference for that person.
For example, someone who is allergic to a medicine’s dye may need a compounded medicine without that dye. The prescriber still has to decide whether the change meets the legal rule for that patient.
Paying less is not the significant difference required by this rule.
What absence from an FDA page does not tell you
FDA publishes a page about safety concerns with certain compounding ingredients. The November 3, 2026 check found no entry for PT-141 or bremelanotide in either of its tables.
That FDA page identifies its content as current on April 22, 2026.
An absent name does not amount to permission to compound it or a finding that it is safe.
A table can answer whether a name appears there. It cannot answer every legal question about a finished product. If someone uses a missing entry as proof, ask which rule applies to the proposed preparation instead.
If a list search is offered as proof, ask how that record establishes the status of the exact prescription. Keep the question specific: which product, which proposed use and what supports that route?
Research labels do not make a care route
PT-141 appeared among the human-use products described in the FDA letters checked for this handbook on November 3, 2026.
The agency said website claims could show a product was meant for people, despite a research label.
Those letters are allegations to particular firms, rather than court findings.
They are a reason to separate research chemical advertising from a prescription discussion. A preparation labeled for research does not inherit Vyleesi’s approval because its page uses the bremelanotide name.
If the product description cannot be made clear, there is still a question to resolve. Keep any proposed instructions with the prescriber and pharmacist; a web calculator cannot establish the product’s identity.